Bird & Bird London acted for AXIO Data Group on the sale of Vidal Group to Japanese listed M3, Inc.


AXIO, backed by Electra Partners, operates a portfolio of market-leading information businesses, serving customers in a range of sectors including healthcare, aviation, forest products and intellectual property licensing. Bird & Bird previously acted for AXIO on its sales of JOC (2014), Breakbulk (2014), MIMs (2015), Iasist (2015) and MRO Network (2015). Most recently Bird & Bird acted for AXIO on its acquisition of Chipworks Inc., creating a global leader in the intellectual property and technology services market.

AXIO Data Group entered into a binding offer to sell Vidal Group, a leading European provider of reference drug information for healthcare professionals, to M3, Inc. for €100 million. The proposed transaction is subject to certain conditions including consultation with the relevant works council in France and regulatory approvals.

Chris Bradley, CFO at AXIO, commented: "It is a great pleasure to be working once again with Neil and Shing. This was a complex transaction with multiple stakeholders. The experienced Bird & Bird team has once again proved to be pivotal to the successful execution of the transaction. They were extremely professional and handled the process with great efficiency and patience."


Bird & Bird partners Neil Blundell and Shing Lo, who led the sale with assistance from associates Sarah Evans, Laura Jordan and Justine Abel, commented: "It is a privilege to be working with Chris Bradley and his team again at AXIO. This transaction showcases our M&A expertise. We would like to thank the tireless B&B team for all their support on this transaction."